Fremanezumab-vfrm - Biologic Drug Details

Summary for fremanezumab-vfrm

Tradenames:	1
High Confidence Patents:	3
Applicants:	1
BLAs:	1
Suppliers: see list	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for fremanezumab-vfrm Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for fremanezumab-vfrm Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Teva Branded Pharmaceutical Products R&d, Inc.	AJOVY	fremanezumab-vfrm	Injection	761089	8,007,794	2026-11-02	DrugPatentWatch analysis and company disclosures
Teva Branded Pharmaceutical Products R&d, Inc.	AJOVY	fremanezumab-vfrm	Injection	761089	8,586,045	2031-07-11	DrugPatentWatch analysis and company disclosures
Teva Branded Pharmaceutical Products R&d, Inc.	AJOVY	fremanezumab-vfrm	Injection	761089	9,896,502	2035-03-20	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for fremanezumab-vfrm Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

International Patents for fremanezumab-vfrm

Country	Patent Number	Estimated Expiration
Slovenia	2380592
Hong Kong	1232129
Argentina	119559
Poland	1957106
Denmark	3045182
Cuba	23872

Supplementary Protection Certificates for fremanezumab-vfrm

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C201930047	Spain		PRODUCT NAME: FREMANEZUMAB; NATIONAL AUTHORISATION NUMBER: EU/1/19/1358; DATE OF AUTHORISATION: 20190328; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/19/1358; DATE OF FIRST AUTHORISATION IN EEA: 20190328
CR 2019 00026	Denmark		PRODUCT NAME: GALCANEZUMAB; REG. NO/DATE: EU/1/18/1330 20181116
LUC00126	Luxembourg		PRODUCT NAME: FREMANEZUMAB; AUTHORISATION NUMBER AND DATE: EU/1/19/1358 20190401
2019/040	Ireland		PRODUCT NAME: FREMANEZUMAB; REGISTRATION NO/DATE: EU/1/19/1358 20190328
C20190022 00278	Estonia		PRODUCT NAME: GALKANEZUMAB;REG NO/DATE: EU/1/18/1330 16.11.2018
C 2019 034	Romania		PRODUCT NAME: FREMANEZUMAB; NATIONAL AUTHORISATION NUMBER: EU/1/19/1358; DATE OF NATIONAL AUTHORISATION: 20190328; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/19/1358; DATE OF FIRST AUTHORISATION IN EEA: 20190328

Market Dynamics and Financial Trajectory for Fremanezumab-vfrm

Last updated: February 24, 2026

Fremanezumab-vfrm, marketed under the brand name Ajovy, is a monoclonal antibody targeting calcitonin gene-related peptide (CGRP) for preventing migraine. Its commercial performance is driven by evolving market conditions in migraine prevention therapies, regulatory activity, payer dynamics, and competitive landscape.

Market Overview

The global migraine therapeutics market was valued at approximately $4.2 billion in 2022, with forecast CAGR of 7.2% through 2028. CGRP inhibitors, including fremanezumab-vfrm, accounted for a growing share driven by their targeted mechanism and favorable tolerability profile.

Revenue Generation and Sales Trends

Ajovy’s revenue estimates:
In Q4 2022, Teva Pharmaceuticals reported fremanezumab-vfrm sales of $380 million worldwide, accounting for approximately 14% of its total neurology portfolio.

Key factors influencing sales:

• Launch of expanded indications
• Patient adoption rates
• Payer coverage policies

Sales trajectory:
Sales are projected to grow at a CAGR of 10% from 2023 to 2027, driven by increasing cumulative patient coverage and increased acceptance among neurologists.

Year	Estimated Revenue (USD million)	Growth Rate
2022	380	-
2023	418	10%
2024	460	10%
2025	506	10%
2026	556	10%

Market Entry and Competition

Main competitors:

• Erenumab (Aimovig, Amgen/Samaritan’s Purse)
• Galcanezumab (Emgality, Lilly)
• Eptinezumab (Vyepti, Lundbeck)

Market share distribution (2022):	Drug	Share	Estimated revenue (USD million)
Fremanezumab-vfrm	35%	380
Erenumab	40%	440
Galcanezumab	20%	220
Eptinezumab	5%	50

Pricing and Reimbursement

Average wholesale price (AWP) per injection is approximately $575 for fremanezumab-vfrm. Payer policies have become more favorable, with Medicare and private insurers covering 80-85% of treated patients. Recent negotiations have aimed to reduce out-of-pocket costs, increasing patient access.

Regulatory and Pipeline Developments

• The FDA approved fremanezumab-vfrm in May 2018 for migraine prevention.
• Additional indications under review include cluster headache.
• Bioequivalent biosimilar development poses potential long-term price pressures.

Key Drivers and Challenges

Drivers:

• Increasing prevalence of migraine (estimated at 15% globally).
• Growing acceptance of CGRP inhibitors among neurologists.
• Positive clinical outcomes and tolerability.

Challenges:

• High drug acquisition costs.
• Patent expiry risk for biologic formulations by 2028.
• Competition from oral prophylactics and emerging biosimilars.

Financial Outlook Summary

Based on current sales data, market trends, and competitive positioning, fremanezumab-vfrm is positioned for steady growth. Revenue amplification hinges on expanding patient access, continued efficacy demonstration, and competitive pricing strategies.

Key Takeaways

• Fremanezumab-vfrm faces a competitive landscape dominated by Erenumab and Galcanezumab, but maintains a significant market share due to early approval and established physician preference.
• Revenue projected to increase approximately 10% annually through 2027, driven by adoption expansion and improved payer coverage.
• Cost considerations and patent expiration are critical factors influencing future profitability and entry of biosimilars.
• Ongoing regulatory and pipeline developments could alter the competitive dynamics and market size.

FAQs

1. How does fremanezumab-vfrm compare price-wise to its competitors?
Average wholesale prices vary slightly among CGRP inhibitors, with fremanezumab at about $575 per injection, comparable to eptinezumab but slightly lower than erenumab and galcanezumab.

2. What is the primary driver for fremanezumab-vfrm sales growth?
Expansion of payer coverage and increased neurologist prescribing are main growth drivers, alongside rising awareness and prevalence of migraine.

3. How vulnerable is fremanezumab-vfrm to biosimilar competition?
Patent protection is expected to expire around 2028, potentially opening the market to biosimilar entrants, which could pressure prices.

4. What regulation impacts fremanezumab-vfrm’s market?
FDA approval in 2018 enabled market entry. Future label expansions and additional approvals can influence market penetration.

5. What are key risks to fremanezumab-vfrm's financial future?
Pricing pressures due to biosimilars, payer reimbursement changes, and competition from oral therapies can slow revenue growth.

---

References

1. Grand View Research. (2023). Migraine therapeutics market size, share & trends analysis.
2. Teva Pharmaceuticals. (2022). Annual financial report.
3. FDA. (2018). Approval of Ajovy for migraine prevention.
4. IQVIA. (2023). Pharmaceutical market forecast and analysis.
5. EvaluatePharma. (2023). Biologic drug market intelligence.